FDA Clears New Ready-to-Use Romidepsin Formulation for Lymphoma Treatment

The U.S. FDA has approved a new ready-to-use romidepsin injection solution by Amneal Pharmaceuticals. This formulation is intended for adult patients with cutaneous T-cell lymphoma who have undergone previous systemic therapies. The approval offers a more convenient alternative to existing treatments, potentially enhancing safety and operational efficiency in healthcare settings.